$DT

Dynatrace, Inc.

AlphAI earnings readQ1 FY2027 · AUG 5 · NEXT NOV 3Dynatrace Reports First Quarter Fiscal Year 2027 Financial ResultsVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

3
1
0

No SEC Form 4 filings for $DT in the last 30 days.

See all $DT insider activity →
Med

TD Cowen raises Dynatrace stock price target on DPS upside view

TD Cowen raised its price target for Dynatrace (NYSE:DT) to $68 from $62, citing expectations of a modest beat in net new annual recurring revenue and an anticipated guidance increase to 18%. The firm sees upside from DPS renewals. DT shares are up 30% since the last earnings report, trading at $65.38. Analysts generally view the stock as undervalued with growth potential.

DT Maintained by UBS -- Price Target Raised to $80.00

UBS analyst Radi Sultan maintained a 'Buy' rating on Dynatrace (DT) and raised the price target to $80.00 from $74.00. GuruFocus values DT at $71.08, suggesting a 9.9% undervaluation. The company has a GF Score of 93/100, indicating strong performance. Insiders have sold $2.87M in shares over the last three months.

DT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning DT (Dynatrace, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.

Recent DT coverage spans financial news, market movers and regulation.

What's driving DT

AlphAI scores every news story that mentions DT with an AI model for sentiment and relevance, and aggregates insider trades from Dynatrace, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DT

Score
$DTMed

TD Cowen raises Dynatrace stock price target on DPS upside view

TD Cowen raised its price target for Dynatrace (NYSE:DT) to $68 from $62, citing expectations of a modest beat in net new annual recurring revenue and an anticipated guidance increase to 18%. The firm sees upside from DPS renewals. DT shares are up 30% since the last earnings report, trading at $65.38. Analysts generally view the stock as undervalued with growth potential.

$DTMed

DT Maintained by UBS -- Price Target Raised to $80.00

UBS analyst Radi Sultan maintained a 'Buy' rating on Dynatrace (DT) and raised the price target to $80.00 from $74.00. GuruFocus values DT at $71.08, suggesting a 9.9% undervaluation. The company has a GF Score of 93/100, indicating strong performance. Insiders have sold $2.87M in shares over the last three months.

Top Bank Names 3 Software Stocks Its Top Picks for 2026

BMO Capital Markets added Dynatrace (DT) and ServiceNow (NOW) to its top software picks for 2026, maintaining Outperform ratings and raising price targets for both. Okta (OKTA) was also included, with the analyst noting higher expectations ahead of its earnings. ServiceNow's performance obligations are expected to grow 20% YoY in Q3, with organic growth potentially reaching 20%.

$DTHigh

Why is Dynatrace stock climbing today?

Dynatrace (DT) stock rose 2.0% to $64.79, hitting a 52-week high of $65.18, after RBC Capital and Barclays raised price targets to $73 and $71, respectively. The company also announced FedRAMP Class D status, potentially expanding its market. The S&P 500 was flat, and the Nasdaq was modestly lower.

$DTMed

Federal certification advances for Dynatrace, but full certification is still ahead.

Dynatrace's AI-powered observability platform has advanced to Class D (High) 'Initial Implementation' status, allowing federal agencies to use it for sensitive workloads. The company is working toward full certification, which would enable access to its full platform, including Grail®, at the highest federal security tier. Dynatrace is integrating compliance requirements into its newest platform generation.

Related tickers